Ipamorelin & CJC-1295: The GH Pulse Stack Research Guide (2026)

Ipamorelin is a pentapeptide GHRP (Growth Hormone Releasing Peptide) that acts selectively on the GHS-R1a receptor (Growth Hormone Secretagogue Receptor type 1a) in the pituitary gland. Its binding triggers a downstream signalling cascade that stimulates somatotroph cells to release GH. What makes Ipamorelin particularly valuable in the research context is its selectivity: unlike the earlier GHRPs (GHRP-2 and GHRP-6), Ipamorelin does not significantly elevate cortisol, ACTH, or prolactin at research doses. This hormonal cleanliness makes it far more useful for protocol design where stimulating GH without adrenal stress activation is the goal. The Tier C rating reflects solid preclinical and early human data, with dose-response pharmacokinetics established in human volunteers, but without the large-scale RCT evidence required for Tier A or B.

CJC-1295 (also called Modified GRF 1-29 in its no-DAC form) is an analog of the first 29 amino acids of Growth Hormone Releasing Hormone (GHRH), modified at positions 2, 8, 15, and 27 to increase resistance to enzymatic degradation. It acts on the GHRH receptor (GHRH-R) — a completely different receptor class to the GHS-R1a targeted by Ipamorelin. CJC-1295 no-DAC has a short plasma half-life of approximately 30 minutes, producing a single pulsatile GH release per injection that closely mirrors the natural pulsatile GH secretion pattern. Multiple human pharmacokinetic studies have characterised its dose-response profile and GH stimulation kinetics, earning it a Tier B rating. The pulsatile kinetic profile (rather than sustained elevation) is considered physiologically preferable for maintaining receptor sensitivity across a research cycle.

Ipamorelin and CJC-1295 no-DAC act on two distinct receptor systems in the GH axis. Ipamorelin acts on GHS-R1a (the ghrelin receptor pathway), stimulating GH release via a calcium-dependent signalling cascade in pituitary somatotrophs. CJC-1295 no-DAC acts on GHRH-R (the GHRH receptor pathway), stimulating GH release via a cAMP-dependent signalling cascade in the same cells. These two pathways converge at the level of GH exocytosis, and when both are simultaneously activated, the combined GH release is significantly greater than either alone — estimated at 3–5× in preclinical models. This is not simply additive receptor stimulation; it reflects the synergistic convergence of two independent signalling cascades at the same downstream output. Additionally, the somatostatin rebound window — the natural suppressive feedback that limits GH pulse duration — can be timed against injection to maximise the usable peak.

Standard research protocol for the GH Pulse Stack: 200 mcg Ipamorelin + 200 mcg CJC-1295 no-DAC, administered as a single subcutaneous injection, once daily, pre-sleep in a fully fasted state. The pre-sleep, fasted administration is mechanistically important: the largest natural GH pulse of the 24-hour cycle occurs during slow-wave sleep onset (~90 minutes after falling asleep). Injecting pre-sleep amplifies this natural pulse. The fasted state is essential because insulin — elevated after any carbohydrate-containing meal — suppresses GHRH signalling and reduces GH pulse magnitude significantly. Last food intake should be at least 2 hours before injection for minimal insulin interference, ideally 3 hours. Cycle: 12 weeks on, 4 weeks off before repeating. The off-cycle preserves receptor sensitivity for the subsequent protocol period.

CJC-1295 DAC (with Drug Affinity Complex) is a modified form that uses maleimidoproprionic acid (MPA) bioconjugation technology to bind to circulating serum albumin after injection. This albumin binding dramatically extends the effective half-life from 30 minutes (no-DAC) to approximately 8 days, making once-weekly administration viable. DAC is used when sustained GH elevation — rather than pulsatile release — is the research objective. A common hybrid protocol uses CJC-1295 DAC 2mg once weekly (in a dedicated solo weekly pen) alongside Ipamorelin 200mcg daily (in a separate daily pen). This provides a sustained GH floor from the DAC component with daily Ipamorelin pulses amplifying on top. The key consideration: the sustained GH elevation profile of DAC suppresses the natural GH axis pulsatility more significantly than the no-DAC formulation. Researchers focused on preserving physiological GH dynamics prefer no-DAC.

Sermorelin (GHRH 1-29) is the original GHRH analog and holds the strongest evidence tier of any GH-axis research peptide — Tier A — based on multiple published human clinical studies, including controlled trials in growth hormone deficiency and aging populations. It is the natural first 29 amino acids of GHRH with no modifications, giving it a shorter half-life and lower potency than CJC-1295 no-DAC but a substantially better-characterised human safety profile. For researchers aged 40 and above — where age-related GH decline is the primary research context — or for those seeking the most conservative GH-axis starting point, Sermorelin is the recommended first compound. Its action is more modest, its evidence base is stronger, and its long-term safety data is more mature. Researchers can progress from Sermorelin to the full GH Pulse Stack once a baseline is established.

GH-axis peptide research requires specific bloodwork monitoring because elevated GH and IGF-1 can affect insulin sensitivity and glucose metabolism. The essential pre-protocol panel includes: Fasting Glucose — baseline before any GH-axis peptide and the primary safety monitoring marker throughout; HbA1c — reflects 90-day average blood glucose, the gold standard for longitudinal glycaemic assessment; Fasting Insulin + HOMA-IR — quantifies insulin sensitivity directly; IGF-1 — the downstream proxy for GH axis activity, used to assess protocol response. Additionally, Total and Free Testosterone, SHBG, LH, FSH provide hormonal context and baseline. Cortisol provides a stress axis baseline. Fasting Glucose and HbA1c should be rechecked at the 8-week mark. IGF-1 at cycle end provides the best assessment of GH axis response to the protocol.

Myth 1: "GH peptides cause cancer." No evidence demonstrates that GH-axis peptides at research doses cause cancer in healthy subjects without pre-existing malignancy. The concern is theoretical and context-specific: individuals with active or suspected malignancies should not engage in GH-axis peptide research. In healthy subjects, the transient pulsatile GH elevations are within physiological ranges and not associated with oncogenic risk in the available literature. Myth 2: "You need to be GH-deficient to benefit from research." Research into GH-axis peptides spans optimisation contexts (age-related GH decline, metabolic health) as well as deficiency. The research interest is not limited to clinical deficiency. Myth 3: "CJC-1295 and Ipamorelin do the same thing." They act on completely different receptor classes — combining them is not redundant, it is synergistic by design. Myth 4: "More frequent dosing produces more effect." Twice-daily dosing does not produce proportionally greater results and disrupts the pulsatile architecture that makes the GH Pulse Stack effective. Pre-sleep once-daily is the evidence-supported protocol.